CSIMarket
 


Alaunos Therapeutics Inc   (TCRT)
Other Ticker:  
 

Cumulative Alaunos Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

TCRT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

TCRT Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -85.77 % -81.13 % -19.64 % 50.65 % 16.67 %
Y / Y Current Assets Growth -76.81 % -69.4 % -45.27 % -31.75 % -42.51 %
Working Capital Ratio for Trailing Twelve Months Period 2.43 2.1 2.07 2.29 2.74
Total Ranking # 1499 # 1824 # 2017 # 2091 # 1740
Seq. Current Liabilities Growth -7.44 % -70.39 % -29.39 % -26.48 % 22.76 %
Seq. Current Assets Growth -31.47 % -50.82 % -29.02 % -3.07 % -9.54 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Current Liabilities decreased faster than Alaunos Therapeutics Inc 's average Current Assets, this led to increase in in Alaunos Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period to 2.43, Working Capital Ratio for Trailing Twelve Months Period remained below Alaunos Therapeutics Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 335 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Alaunos Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about TCRT
Working Capital Ratio TCRT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 336
Sector # 633
S&P 500 # 1322


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
10.21 5.61 2.07
(Jun 30 2020)   (Mar 31 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Homology Medicines Inc  6.58 
Vistagen Therapeutics Inc   6.57 
Roivant Sciences Ltd   6.57 
Protagenic Therapeutics Inc new  6.57 
China Health Industries Holdings Inc   6.44 
Verastem inc   6.42 
Mei Pharma Inc   6.36 
Hcw Biologics Inc   6.34 
Albireo Pharma inc   6.32 
Salarius Pharmaceuticals inc   6.27 
Tharimmune Inc   6.23 
Synlogic Inc   6.23 
Carisma Therapeutics Inc   6.22 
Rain Oncology Inc   6.19 
Nuvectis Pharma inc   6.18 
Alterity Therapeutics Limited  6.17 
Chemomab Therapeutics Ltd   6.15 
Regeneron Pharmaceuticals Inc   6.13 
Cara Therapeutics inc   6.13 
Xilio Therapeutics Inc   6.08 
Opiant Pharmaceuticals Inc   6.05 
Hepion Pharmaceuticals inc   6.04 
Immunic Inc   6.01 
Gossamer Bio Inc   5.91 
Foghorn Therapeutics Inc   5.87 
Syros Pharmaceuticals Inc   5.87 
Phibro Animal Health Corporation  5.85 
Lipella Pharmaceuticals Inc   5.84 
Tricida Inc   5.84 
Plx Pharma Inc   5.81 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com